Do you want to read an article? Please log in or register.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib
Lymphoma
Related content
SPECIAL REPORT
Myeloproliferative Neoplasms (MPNs)
Traitement de deuxième ligne de la myélofibrose
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Lancet Haematol.
Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S
doi: 10.1016/
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Br J Haematol.
Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R
doi: 10.1111/bjh.15497.
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
Ann Hematol.
Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villivà N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R
doi: 10.1007/s00277-016-2884-7.
RECOMMENDED
Breast Cancer
Survival of Patients with First and Metachronous Second Primary Breast Cancer or Lung Cancer Malignancy: Comparisons Using the SEER Database
★ 1
Recommended by
Dr Martin Frey, Faculty Member
doi: 10.1007/s12325-020-01322-0.
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
JAMA Oncol.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S
doi: 10.1001/
Myeloproliferative Neoplasms (MPNs)
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Br J Haematol.
Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM
doi: 10.1111/bjh.16462.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Hematol Oncol.
Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F
doi: 10.1002/hon.2509.
RECOMMENDED
Head and Neck Cancer
Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients
Strahlenther Onkol.
Elicin O, Sermaxhaj B, Bojaxhiu B, Shelan M, Giger R, Rauch D, Aebersold DM
doi: 10.1007/s00066-018-1400-5